Arch Biopartners Inc. (ARCH.V)
CAD 1.73
(-0.57%)
CAD 1.73
(-0.57%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 5.01 Million CAD | 13.67% |
| 2022 | 4.41 Million CAD | -14.54% |
| 2021 | 5.16 Million CAD | 52.31% |
| 2020 | 3.39 Million CAD | 17.51% |
| 2019 | 2.88 Million CAD | 94.51% |
| 2018 | 1.48 Million CAD | 324.46% |
| 2017 | 349.44 Thousand CAD | 5.82% |
| 2016 | 330.21 Thousand CAD | 0.59% |
| 2015 | 328.27 Thousand CAD | -7.13% |
| 2014 | 353.47 Thousand CAD | -10.77% |
| 2013 | 396.14 Thousand CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | -100.0% |
| 2008 | 1.64 Million CAD | 21.42% |
| 2007 | 1.35 Million CAD | 43.91% |
| 2006 | 940.38 Thousand CAD | -11.16% |
| 2005 | 1.05 Million CAD | -8.19% |
| 2004 | 1.15 Million CAD | 103.56% |
| 2003 | 566.41 Thousand CAD | 0.0% |
| 2002 | - CAD | -100.0% |
| 2001 | 118.37 Thousand CAD | 0.0% |
| 2000 | - CAD | 0.0% |
| 1999 | - CAD | 0.0% |
| 1998 | - CAD | 0.0% |
| 1997 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 5.32 Million CAD | 3.8% |
| 2024 Q2 | 5.12 Million CAD | 1.84% |
| 2024 Q1 | 5.03 Million CAD | 0.41% |
| 2023 Q4 | 5.01 Million CAD | 0.76% |
| 2023 FY | 5.01 Million CAD | 13.67% |
| 2023 Q2 | 5.92 Million CAD | 34.85% |
| 2023 Q1 | 4.39 Million CAD | -0.49% |
| 2023 Q3 | 4.97 Million CAD | -15.93% |
| 2022 Q1 | 4.38 Million CAD | -15.09% |
| 2022 Q4 | 4.41 Million CAD | 0.57% |
| 2022 FY | 4.41 Million CAD | -14.54% |
| 2022 Q2 | 4.36 Million CAD | -0.49% |
| 2022 Q3 | 4.38 Million CAD | 0.57% |
| 2021 Q1 | 3.39 Million CAD | 0.01% |
| 2021 Q2 | 3.39 Million CAD | 0.01% |
| 2021 Q3 | 5.64 Million CAD | 66.4% |
| 2021 Q4 | 5.16 Million CAD | -8.49% |
| 2021 FY | 5.16 Million CAD | 52.31% |
| 2020 Q3 | 3.39 Million CAD | 0.13% |
| 2020 FY | 3.39 Million CAD | 17.51% |
| 2020 Q1 | 2.88 Million CAD | 0.15% |
| 2020 Q2 | 3.39 Million CAD | 17.46% |
| 2020 Q4 | 3.39 Million CAD | -0.23% |
| 2019 Q2 | 1.94 Million CAD | 34.22% |
| 2019 Q4 | 2.88 Million CAD | -2.04% |
| 2019 Q3 | 2.94 Million CAD | 51.81% |
| 2019 Q1 | 1.44 Million CAD | -2.55% |
| 2019 FY | 2.88 Million CAD | 94.51% |
| 2018 Q1 | 849.61 Thousand CAD | 143.13% |
| 2018 FY | 1.48 Million CAD | 324.46% |
| 2018 Q3 | 1.46 Million CAD | 0.96% |
| 2018 Q2 | 1.45 Million CAD | 70.68% |
| 2018 Q4 | 1.48 Million CAD | 1.31% |
| 2017 Q3 | 319.88 Thousand CAD | -4.28% |
| 2017 Q1 | 334.16 Thousand CAD | 1.19% |
| 2017 Q2 | 334.19 Thousand CAD | 0.01% |
| 2017 Q4 | 349.44 Thousand CAD | 9.24% |
| 2017 FY | 349.44 Thousand CAD | 5.82% |
| 2016 Q4 | 330.21 Thousand CAD | -0.79% |
| 2016 Q3 | 332.83 Thousand CAD | -1.59% |
| 2016 Q2 | 338.2 Thousand CAD | 1.5% |
| 2016 Q1 | 333.2 Thousand CAD | 1.5% |
| 2016 FY | 330.21 Thousand CAD | 0.59% |
| 2015 Q3 | 321.54 Thousand CAD | 1.31% |
| 2015 Q4 | 328.27 Thousand CAD | 2.09% |
| 2015 Q1 | 326.2 Thousand CAD | -7.71% |
| 2015 Q2 | 317.39 Thousand CAD | -2.7% |
| 2015 FY | 328.27 Thousand CAD | -7.13% |
| 2014 Q1 | 25.2 Thousand CAD | -93.64% |
| 2014 Q4 | 353.47 Thousand CAD | -3.98% |
| 2014 Q3 | 368.11 Thousand CAD | -3.85% |
| 2014 Q2 | 382.86 Thousand CAD | 1419.29% |
| 2014 FY | 353.47 Thousand CAD | -10.77% |
| 2013 Q4 | 396.14 Thousand CAD | 2.14% |
| 2013 FY | 396.14 Thousand CAD | 0.0% |
| 2013 Q3 | 387.83 Thousand CAD | 2.77% |
| 2013 Q2 | 377.38 Thousand CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2009 FY | - CAD | -100.0% |
| 2009 Q1 | 1.64 Million CAD | -47.87% |
| 2009 Q2 | 1.18 Million CAD | -27.61% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 Q3 | - CAD | -100.0% |
| 2008 FY | 1.64 Million CAD | 21.42% |
| 2008 Q1 | 1.35 Million CAD | -21.85% |
| 2008 Q2 | 1.98 Million CAD | 46.5% |
| 2008 Q3 | 2.34 Million CAD | 18.14% |
| 2008 Q4 | 3.15 Million CAD | 34.58% |
| 2007 Q3 | 1 Million CAD | 4.73% |
| 2007 Q1 | 940.38 Thousand CAD | -15.76% |
| 2007 Q2 | 956.05 Thousand CAD | 1.67% |
| 2007 FY | 1.35 Million CAD | 43.91% |
| 2007 Q4 | 1.73 Million CAD | 72.95% |
| 2006 FY | 940.38 Thousand CAD | -11.16% |
| 2006 Q4 | 1.11 Million CAD | 8.46% |
| 2006 Q3 | 1.02 Million CAD | 3.46% |
| 2006 Q2 | 994.81 Thousand CAD | -6.02% |
| 2006 Q1 | 1.05 Million CAD | -2.24% |
| 2005 Q4 | 1.08 Million CAD | 17.16% |
| 2005 Q3 | 924.18 Thousand CAD | -11.64% |
| 2005 Q2 | 1.04 Million CAD | -9.28% |
| 2005 Q1 | 1.15 Million CAD | -0.83% |
| 2005 FY | 1.05 Million CAD | -8.19% |
| 2004 Q3 | 1.2 Million CAD | 54.09% |
| 2004 Q1 | 566.41 Thousand CAD | 0.0% |
| 2004 Q2 | 782.35 Thousand CAD | 38.12% |
| 2004 FY | 1.15 Million CAD | 103.56% |
| 2004 Q4 | 1.16 Million CAD | -3.56% |
| 2003 Q4 | - CAD | 0.0% |
| 2003 Q3 | - CAD | 0.0% |
| 2003 Q2 | - CAD | 0.0% |
| 2003 Q1 | - CAD | -100.0% |
| 2003 FY | 566.41 Thousand CAD | 0.0% |
| 2002 FY | - CAD | -100.0% |
| 2002 Q4 | 50 Thousand CAD | 0.0% |
| 2002 Q2 | - CAD | -100.0% |
| 2002 Q3 | 50 Thousand CAD | 0.0% |
| 2002 Q1 | 118.37 Thousand CAD | 0.0% |
| 2001 Q1 | - CAD | 0.0% |
| 2001 Q2 | - CAD | 0.0% |
| 2001 Q3 | - CAD | 0.0% |
| 2001 FY | 118.37 Thousand CAD | 0.0% |
| 2000 FY | - CAD | 0.0% |
| 2000 Q1 | - CAD | 0.0% |
| 1999 Q1 | - CAD | 0.0% |
| 1999 FY | - CAD | 0.0% |
| 1998 FY | - CAD | 0.0% |
| 1998 Q4 | - CAD | 0.0% |
| 1998 Q2 | - CAD | 0.0% |
| 1998 Q3 | - CAD | 0.0% |
| 1997 FY | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Covalon Technologies Ltd. | 1.56 Million CAD | -221.043% |
| Hemostemix Inc. | 4.32 Million CAD | -16.075% |
| Universal Ibogaine Inc. | 1.73 Million CAD | -188.673% |
| Kane Biotech Inc. | 8.27 Million CAD | 39.389% |
| MedMira Inc. | 9.27 Million CAD | 45.895% |
| Marvel Biosciences Corp. | 1 Million CAD | -401.619% |
| NervGen Pharma Corp. | 197.19 Thousand CAD | -2443.835% |
| XORTX Therapeutics Inc. | 15.17 Thousand CAD | -32951.249% |